ESR2 and non-small cell lung carcinoma: Small molecule inhibitors are often combined with monoclonal antibodies such as erlotinib and the monoclonal antibody Erb/HER which neutralize tyrosine kinases and demonstrated efficacy in non-small cell lung cancer (NSCLC) in vitro and in vivo [15].